Exondys 51

Sarepta shares first results on next-generation Duchenne drug
BioPharma Dive
Tue, 12/8/20 - 11:13 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Exondys 51
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Sat, 11/30/19 - 11:18 pm
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
The FDA and Sarepta: a window into the real world of drug regulation
Stat
Tue, 09/3/19 - 04:42 pm
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Sarepta's Lone Analyst Skeptic Takes On 22 Bulls With Renewed Warnings
Bloomberg
Mon, 08/19/19 - 10:28 am
Sarepta Therapeutics
analysts
Duchenne Muscular Dystrophy
Vyondys 53
Exondys 51
Four New Drugs are Around the Corner. Here’s What You Need to Know.
Xconomy
Thu, 08/15/19 - 11:39 pm
FDA
drug approvals
AbbVie
Upadacitinib
Exondys 51
Sarepta Therapeutics
Nabriva Therapeutics
lefamulin
Roche
Rozlytrek
Studies Show Sarepta's Exondys 51 Slows Respiratory Decline in Muscular Dystrophy Patients
BioSpace
Wed, 07/10/19 - 04:31 pm
Sarepta Therapeutics
Exondys 51
DMD
Duchenne Muscular Dystrophy
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Thu, 05/23/19 - 10:08 am
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Fri, 09/21/18 - 09:49 am
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Thu, 05/3/18 - 11:14 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal
Endpoints
Fri, 04/6/18 - 07:39 pm
Sarepta Therapeutics
patients
patents
Exondys 51
Duchenne Muscular Dystrophy
Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end
Stat
Mon, 03/12/18 - 09:37 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
golodirsen
Exondys 51
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
BioPharma Dive
Mon, 11/13/17 - 08:46 pm
Anthem
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
3 Biotech Stocks That Could Soar in September
Motley Fool
Sun, 08/27/17 - 06:26 pm
biotech
fitusiran
Alnylam
PTC Therapeutics
Translarna
Sarepta
Exondys 51
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Tue, 07/18/17 - 09:28 am
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
Sat, 03/11/17 - 11:59 am
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Sarepta May Have More Upside After Sales Data
Seeking Alpha
Thu, 01/19/17 - 11:47 am
Sarepta
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Wed, 01/11/17 - 09:57 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
Fri, 12/23/16 - 10:01 am
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Wed, 12/21/16 - 10:52 am
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy

Pages